Zhejiang Xinguang Pharmaceutical Co Ltd

Xinguang Pharmaceutical released its 2026 interim report on August 25, 2026. The company's total operating revenue was 143 million yuan, net profit attributable to the parent company was 39.7121 million yuan, and net cash inflow from operating activities was 57.7783 million yuan. The company's latest asset-liability ratio was 6.05%, gross margin was 46.06%, ROE was 4.79%, and diluted earnings per share was 0.25 yuan. The company's latest total asset turnover was 0.16 times, and inventory turnover was 2.13 times. The number of shareholders was 13,600, and the top ten shareholders held 88.8191 million shares, accounting for 55.51% of the total share capital.

Xinguang Pharmaceutical released its 2026 interim report. Net profit attributable to the parent in the first half was 39.71 million yuan, up 24.5% year on year. Operating revenue was 143 million yuan, up 1.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 36.21 million yuan, up 23.0% year on year. Net cash flow from operating activities was 57.78 million yuan, up 56.9% year on year. In the second quarter, net profit attributable to the parent was 13.34 million yuan, up 81.2% year on year. The company said it will continue to focus on the research, development, production and sales of proprietary Chinese medicines, chemical drugs and health foods.